Results 161 to 170 of about 49,721 (234)

AZD6738 (Ceralasertib) Enhances Trifluridine's Antitumor Effect in 5‐FU–Resistant Colorectal Cancer Cells

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Resistance to 5‐fluorouracil (5‐FU) remains a major obstacle in colorectal cancer (CRC) treatment. Trifluridine (FTD), the active component of TAS‐102, exerts cytotoxicity through DNA incorporation and reportedly remains active in 5‐FU‐resistant tumors, though with limited clinical efficacy.
Shuhei Uehara, Takuya Suzuki, Junki Kato, Hiroyuki Asai, Akira Kato, Shinnosuke Harata, Hajime Ushigome, Yushi Yamakawa, Takahisa Hirokawa, Hiroki Takahashi, Yoichi Matsuo, Shuji Takiguchi   +11 more
wiley   +1 more source

Gemcitabine plus nab-paclitaxel in Japan

Annals of Oncology, 2016
Tatsuya Ioka, Kazuhiro Katayama, Kazuyoshi Ookawa, Hidenori Takahashi, Teruki Teshima   +4 more
openaire   +1 more source

Laryngeal NUT Carcinoma With BRD4::NUTM1 Fusion: A 4‐Year Clinical Course Highlighting the Limitations of Current Multimodal Therapy

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Nuclear protein in testis (NUT) carcinoma is a rare, aggressive malignancy driven by NUTM1 rearrangement, often misdiagnosed as squamous cell carcinoma, with no established standard therapy. This report describes the clinical course and treatment resistance in primary laryngeal NUT carcinoma and provides insights into potential ...
Masafumi Kanno, Chiai Sasaki, Eiichi Kato, Hoshino Terada, Nobuhiro Hanai, Eiichi Sasaki, Mana Fukushima, Toshiki Masuishi, Keisuke Takanari, Yasuto Fukada, Yuto Miyazaki, Yuki Sonoda, Yukinori Kato, Taiyo Morikawa, Tetsuji Takabayashi, Shigeharu Fujieda   +15 more
wiley   +1 more source

Progesterone Is Associated With Increased Vasohibin‐2 Expression, Tubulin Detyrosination, and Paclitaxel Sensitivity in PR‐Negative Ovarian Cancer Cells

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Progesterone induces rapid cellular responses in progesterone receptor (PR)‐negative ovarian cancer cells that are consistent with non‐genomic progesterone signaling. Vasohibin‐2 (VASH2), originally identified as a pro‐angiogenic factor, has recently been recognized as a tubulin carboxypeptidase involved in microtubule regulation ...
Takahiro Koyanagi, Yasushi Saga, Yoshifumi Takahashi, Kohei Tamura, Eri Suizu, Kazuki Yamamoto, Akiyo Taneichi, Yuji Takei, Hiroaki Mizukami, Hiroyuki Fujiwara   +9 more
wiley   +1 more source

Prospective Phase II Trial of Biweekly Gemcitabine Plus Nab‐Paclitaxel as First‐Line Therapy in Patients Aged 75 Years and Older With Unresectable Pancreatic Cancer

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Although older adults (≥ 75 years) constitute a large proportion of patients with unresectable pancreatic cancer (PC), they remain underrepresented in clinical trials. Biweekly gemcitabine plus nab‐paclitaxel (GnP) has been evaluated in retrospective studies as an alternative dosing schedule, whereas prospective evidence remains ...
Kenji Ikezawa, Toshihiro Imai, Ryoji Takada, Takuo Yamai, Nobuyasu Fukutake, Makiko Urabe, Yugo Kai, Kaori Mukai, Tasuku Nakabori, Kazuyoshi Ohkawa   +9 more
wiley   +1 more source

4‐Hydroxytamoxifen induces a noncanonical ferroptosis in lung adenocarcinoma by targeting AKR1B10

Clinical and Translational Medicine, Volume 16, Issue 9, September 2026.
4‑OHT directly inhibits AKR1B10 enzymatic activity to induce noncanonical ferroptosis in LUAD. AKR1B10 sustains LUAD survival by stabilising ACC1 and detoxifying reactive carbonyl species (RCSs). Nanatinostat similarly targets AKR1B10 and elicits the same cell death modality.
Hui Yang, Yanan Wang, Jiangbo Jin, Hanyan Xu, Yinshui Miao, Xiaojing Wu, Shengsong Chen, Tianyu Han, Qingyuan Zhan   +8 more
wiley   +1 more source

Exploratory single‐nucleus multiomics analysis of myeloid cell states associated with neoadjuvant chemotherapy response in pancreatic ductal adenocarcinoma

Clinical and Translational Medicine, Volume 16, Issue 9, September 2026.
Neoadjuvant‐treated PDAC tumors were stratified into responders and non‐responders based on CAP guidelines snRNA‐seq, snATAC‐seq, and spatial transcriptomics can be used to profile the neoadjuvant‐chemotherapy‐treated PDAC immune landscape. Our exploratory findings nominate candidate myeloid features for validation in larger cohorts and functional ...
Mercy Ojetunde, Li Ma, Hillary G. Goodney, Alyson M. Stevens, Alan Mizener, Emidio E. Pistilli, Sascha Ott, Kawther Abdilleh, Barbara Szomolay, Gangqing Hu, Timothy D. Eubank, Brian A. Boone   +11 more
wiley   +1 more source

Bevacizumab plus nab‐paclitaxel and platinum as second‐line therapy for driver‐gene‐negative non‐squamous non‐small cell lung cancer after immunochemotherapy: A prospective single‐arm single‐centre study

Clinical and Translational Medicine, Volume 16, Issue 9, September 2026.
This study prospectively evaluated the efficacy and safety of the bevacizumab, nab‐paclitaxel and platinum combination as a second‐line therapy for driver‐gene‐negative advanced non‐squamous non‐small cell lung cancer after immunochemotherapy. The confirmed objective response rate was 46.4%.
Ying Lin, Yunbo Yu, Zhihuang Hu, Chenchen Wei, Zezhou Wang, Yao Zhang, Zhenhua Wu, Bo Yu, Xinmin Zhao, Hui Yu, Xianghua Wu, Huijie Wang, Jialei Wang   +12 more
wiley   +1 more source

Cinnamaldehyde From Cinnamon as a Food‐Derived Bioactive: Phytochemistry, Anticancer Mechanisms, Bioavailability, Nanoformulation and Safety

Food Frontiers, Volume 7, Issue 5, September 2026.
Cinnamaldehyde derived from Cinnamomum species exerts multitarget anticancer effects by promoting oxidative stress, mitochondrial dysfunction, apoptosis, cell‐cycle arrest, autophagy, and epigenetic changes, and by suppressing mitogen‐activated protein kinase (MAPK), phosphoinositide 3‐kinase/protein kinase B/mechanistic target of rapamycin (PI3K/Akt ...
Gervason Moriasi, Sally Kamau, Gulnaz Seitimova, Shynar Zhumagaliyeva, Javad Sharifi‐Rad, William N. Setzer, Daniela Calina   +6 more
wiley   +1 more source

Natural Product‐Derived Vesicles in Nanotherapeutics

Journal of Extracellular Vesicles, Volume 15, Issue 9, September 2026.
Natural product‐derived vesicles (NPVs) are an emerging nature‐based nanotherapeutic that can deliver bioactive metabolites into the target site and induce beneficial mechanisms. A practical, chronological bench‐to‐bedside approach throughout the entire NPV development process is expected to resolve challenges encountered in NPV studies.
Kartiko Arif Purnomo, Tsong‐Long Hwang
wiley   +1 more source